Company / Return on Equity (ROE)
Eloxx Pharmaceuticals, Inc. Return on Equity (ROE) History
FY2014-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-33.6%
FY2016
5-year range
-161.7% / -33.6%
FY2014-FY2016
Trend
+79.2%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Eloxx Pharmaceuticals, Inc. reports negative total equity of -33.6% in FY2016. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-33.6% in FY2016.
Improved from -146.7% to -33.6% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2016, return on equity (roe) increased 79.2% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -40.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2016 | -33.6% | +79.2% |
| FY2015 | -161.7% | -10.2% |
| FY2014 | -146.7% | - |
As of FY2016 · SEC 10-K · Updated Jun 24, 2026